5 mg on two occasions: 7 days prior to dosing with GLPG0259 (on day -7) and on day 14 at the same time as the last GLPG0259 dose. GLPG0259 free base (10 mg/mL in 40% [w/v] hydroxypropyl-ß–cyclodextrin, pH 3) or a matching placebo was administered once daily for 14 days, using a syringe, as for study 1. Subjects in the 50 mg dose group were additionally administered an oral dose of methotrexate 7.5 mg (3 tablets of Ledertrexate® 2.5 mg; Wyeth-Pfizer) on two occasions. A dose of 4 mg of folic acid (Folavit®; Kela Pharma Selleckchem MM-102 NV) was administered 24 hours after each methotrexate administration as a preventive measure for methotrexate toxicity. Folic acid was administered after all safety and pharmacokinetic

assessments had been done. Blood samples for pharmacokinetics were collected at regular intervals over 24 hours (on days 1 and 13 [in the 50 mg cohort only]) or over 7 days after the last dose on day 14 (i.e. up to day 21) to assess plasma concentrations of GLPG0259. Blood check details sample handling was similar to that described for study 1. For methotrexate (in the 50 mg cohort only), CH5424802 blood samples were collected at regular intervals over

24 hours (on day -7 and day 14) in tubes containing lithium heparinate, in order to obtain plasma, and were stored at -20°C until analysis. Study 3: Oral Relative Bioavailability and the Food Effect This was a phase I, open-label, randomized, three-period, three-treatment crossover study to compare the oral bioavailability of a solid dosage form of GLPG0259 (a capsule) relative to an oral solution, and to evaluate the effect of food on oral bioavailability of GLPG0259 formulated as a capsule in healthy subjects (n = 12). The criteria for subject eligibility were the same as those listed for study 1. The treatments consisted of an oral dose of a 50 mg GLPG0259 free-base solution given after an overnight fast (treatment A), a GLPG0259 fumarate capsule (equivalent to 50 mg free base) given after an overnight fast (treatment B), and a GLPG0259

fumarate capsule (equivalent to 50 mg free base) given 30 minutes after the start of Etomidate a high-fat, high-calorie breakfast (treatment C). Each subject was administered treatments A, B, and C in one of the two treatment sequences (i.e. ABC or ACB) determined by a computer-generated randomization schedule. There was at least a 7-day washout period between treatments for each subject. Subjects were admitted to the clinical unit on the evening prior to dosing (day -1) and were confined until 24 hours after the last dose. For treatment A, GLPG0259 free base was administered as 5 mL of 10 mg/mL in 40% (w/v) hydroxypropyl-ß–cyclodextrin (pH 3), using a syringe. A volume of 235 mL of water was given to each subject immediately at the time of dosing. Capsules to be administered for treatments B and C were filled with 50 mg of GLPG0259 as a fumarate salt.